These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 52191)

  • 1. Effect of the common bile acids on the fibrin/fibrinogen fragments in rheumatoid synovial fluid. A possible clue to the ameliorating effect of jaundice in rheumatoid arthritis.
    Andersen RB; Bruusgaard A
    Scand J Rheumatol; 1975; 4(3):158-64. PubMed ID: 52191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Degradation of plasmin-resistant fibrinogen-fibrin breakdown products in rheumatoid synovial fluid by Brinastrase.
    Andersen RB; Gormsen J
    Scand J Rheumatol; 1973; 2(2):81-6. PubMed ID: 4270793
    [No Abstract]   [Full Text] [Related]  

  • 3. Properties of fibrinogen-antigenic material on the rheumatoid synovial membrane and in the rheumatoid synovial fluid.
    Clemmensen I; Andersen RB
    J Lab Clin Med; 1978 Nov; 92(5):678-89. PubMed ID: 712203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinogen-fibrin breakdown products in pathologic synovial fluids. An immunologic study.
    Gormsen J; Andersen RB; Feddersen C
    Arthritis Rheum; 1971; 14(4):503-12. PubMed ID: 4254709
    [No Abstract]   [Full Text] [Related]  

  • 5. Different molecular forms of plasminogen and plasmin produced by urokinase in human plasma and their relation to protease inhibitors and lysis of fibrinogen and fibrin.
    Müllertz S
    Biochem J; 1974 Nov; 143(2):273-83. PubMed ID: 4282470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physicochemical and biological properties of human and canine plasmins.
    Takeda Y; Nakabayashi M
    J Clin Invest; 1974 Jan; 53(1):154-62. PubMed ID: 4128408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrin degradation in the synovial fluid of rheumatoid arthritis patients: a model for extravascular fibrinolysis.
    Carmassi F; de Negri F; Morale M; Song KY; Chung SI
    Semin Thromb Hemost; 1996; 22(6):489-96. PubMed ID: 9122713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The primary plasmin inhibitor in rheumatoid synovial fluid.
    Clemmensen I; Donde R; Andersen RB
    Arthritis Rheum; 1977; 20(7):1354-8. PubMed ID: 143941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elastase- and plasmin-mediated fibrinolysis in rheumatoid arthritis.
    Carmassi F; De Negri F; Morale M; Puccetti R; Chung SI
    Int J Tissue React; 1994; 16(2):89-93. PubMed ID: 7960505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The conversion of streptokinase-plasminogen complex to SK-plasmin complex in the presence of fibrin or fibrinogen.
    Takada Y; Takada A
    Thromb Res; 1989 Apr; 54(2):133-9. PubMed ID: 2526391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Release of B beta peptides from fibrinogen or fibrin in the presence of alpha 2 antiplasmin.
    Takada A; Makino Y; Takada Y
    Thromb Res; 1986 Apr; 42(1):1-9. PubMed ID: 2422782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fibrinolytic activity of the blood and synovial fluid in patients with rheumatoid arthritis].
    Erov NK
    Ter Arkh; 1986; 58(7):73-7. PubMed ID: 2945279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The behavior of alpha2-plasmin inhibitor in fibrinolytic states.
    Aoki N; Moroi M; Matsuda M; Tachiya K
    J Clin Invest; 1977 Aug; 60(2):361-9. PubMed ID: 68962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degradation of human fibrinogen by plasms alpha2-macroglobulin-enzyme complexes.
    Harpel PC; Mosesson MW
    J Clin Invest; 1973 Sep; 52(9):2175-84. PubMed ID: 4269529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The extra-articular deposition of fibrinogen antigenic material in patients with rheumatoid arthritis.
    Danneskiold-Samsøe B; Clemmensen I; Andersen RB
    Scand J Rheumatol; 1979; 8(2):87-90. PubMed ID: 88067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of DL and DH degradation products in the reactions of the plasmin hydrolysis of fibrinogen and fibrin].
    Rozenfel'd MA; Leonova VB; Khavkina LS
    Izv Akad Nauk SSSR Biol; 1991; (3):334-42. PubMed ID: 1835465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble fibrin preparations inhibit the reaction of plasmin with alpha 2-macroglobulin. Comparison with alpha 2-antiplasmin and leupeptin.
    Anonick PK; Gonias SL
    Biochem J; 1991 Apr; 275 ( Pt 1)(Pt 1):53-9. PubMed ID: 1708234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of inhibition of fibrinolysis and fibrinogenolysis by the end fibrinogen degradation products.
    Khavkina LS; Rozenfeld MA; Leonova VB
    Thromb Res; 1995 Apr; 78(2):173-87. PubMed ID: 7482434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The release of B beta 1-42 from fibrinogen and fibrin by plasmin.
    Hurlet-Jensen A; Koehn JA; Nossel HL
    Thromb Res; 1983 Mar; 29(6):609-17. PubMed ID: 6222508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding of synthetic B knobs to fibrinogen changes the character of fibrin and inhibits its ability to activate tissue plasminogen activator and its destruction by plasmin.
    Doolittle RF; Pandi L
    Biochemistry; 2006 Feb; 45(8):2657-67. PubMed ID: 16489759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.